Ad.IL-12 was administered in doses ranging from 2.5 × 10 10 to 3 × 10 12 viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients ...
ST. LOUIS--(BUSINESS WIRE)--Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results ...
Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS ...
BEVERLY HILLS, Calif., Nov. 10, 2025 /PRNewswire/ -- Williams Cancer Institute ("WCI"), a leading center pioneering the use of intratumoral immunotherapy for late-stage cancer patients, announced that ...
Researchers have developed a liquid gel that solidifies when injected into a solid tumor, is visible on a CT scan, and can slow-release cancer-fighting treatments. Using the gel in combination with ...
Many cancer treatments have achieved cures in mice only to fail in humans. Intensity Therapeutics has studied these failed challengers, and it may have learned why they failed to go the distance. True ...
Reprogramming the tumor microenvironment to increase immune-mediated responses is currently of intense interest. Patients with immune-infiltrated “hot” tumors demonstrate higher treatment response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback